SCHEMBL131502

SCHEMBL131502

COc1cc(-c2[o+]c3cc(O)cc(OC)c3cc2O)cc(OC)c1O

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD38 P28907 8/20 0.84
DPP4 P27487 2/20 0.82
MAOA P21397 1/20 0.82
ALDH1A1 P00352 1/20 0.60
TSHR P16473 1/20 0.60
HSD17B10 Q99714 1/20 0.60
GLO1 Q04760 5/20 0.55
SNCA P37840 3/20 0.55
EGFR P00533 2/20 0.55
KDR P35968 2/20 0.55
EP300 Q09472 2/20 0.55
CREBBP Q92793 2/20 0.55
OR51E2 Q9H255 2/20 0.48
F2 P00734 1/20 0.46
NR1H2 P55055 1/20 0.46
NR1H3 Q13133 1/20 0.46
ALOX5 P09917 1/20 0.40
PTGS2 P35354 1/20 0.40
APP P05067 1/20 0.37
SMPD3 Q9NY59 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29382950 0.96 CD38 (0.84) CD38DPP4MAOAALDH1A1TSHR
Malvidin SCHEMBL21739 0.91 CD38 (1.00) CD38DPP4MAOAALDH1A1TSHR
Malvidin SCHEMBL29406694 0.91 CD38 (1.00) CD38DPP4MAOAALDH1A1TSHR
SCHEMBL12194290 0.91 CD38 (0.77) CD38DPP4MAOAALDH1A1TSHR
SCHEMBL29435838 0.91 CD38 (0.77) CD38DPP4MAOAALDH1A1TSHR
Malvidin SCHEMBL29640416 0.90 DPP4 (1.00) CD38DPP4MAOAALDH1A1TSHR
Malvidin SCHEMBL308690 0.90 DPP4 (1.00) CD38DPP4MAOAALDH1A1TSHR
Malvidin SCHEMBL30683334 0.90 DPP4 (1.00) CD38DPP4MAOAALDH1A1TSHR
SCHEMBL129253 0.88 CD38 (0.70) CD38DPP4MAOAALDH1A1TSHR
Petunidin SCHEMBL21650 0.87 CD38 (1.00) CD38DPP4MAOAALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024191124-A1 ENZYMATIC ELECTRODE AND ENZYMATIC BIOFUEL CELL INCLUDING SAME 서울과학기술대학교 산학협력단 2024-09-19 WO claimed
US-20230355769-A1 COMPOSITIONS, CONTAINERS, AND METHODS RELATED TO FLAVYLIUM EXCIPIENTS Natural Extraction Systems, LLC (US) 2023-11-09 US claimed
US-20230338331-A1 COMPOSITIONS, CONTAINERS, AND METHODS RELATED TO FLAVYLIUM EXCIPIENTS Natural Extraction Systems, LLC (US) 2023-10-26 US claimed
EP-3573748-B1 COLOURED ORGANIC/INORGANIC HYBRID MATERIALS AND METHOD FOR PREPARING SAME CENTRE NAT RECH SCIENT (FR) 2023-04-19 EP claimed
US-12569530-B2 Tannin-based antiproliferative pharmaceutical IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2026-03-10 US disclosed
EP-4674283-A1 A COMPOSITION FOR IMPARTING A CURED MEAT APPEARANCE AND/OR FLAVOUR Kerry Group Services International Limited (IE) 2026-01-07 EP disclosed
US-12453799-B1 Bioadhesive for medical and dental applications IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY (SA) 2025-10-28 US disclosed
EP-4601666-A2 COMPOSITION COMPRISING AQUEOUS PLANT EXTRACT AND/OR ESSENTIAL OIL AND CAFFEINE AND APPLICATION THEREOF FOR IMPROVING COGNITIVE AND MOOD FUNCTIONS The Coca-Cola Company (US) 2025-08-20 EP disclosed
US-20250249063-A1 METHOD FOR TREATING ORAL CANCER IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2025-08-07 US disclosed
US-20250222060-A1 POLYPHENOL COMPOSITION AND METHOD OF ITS USE AND MANUFACTURE IN REDUCING BODY WEIGHT Vidya Herbs, Inc. (US) 2025-07-10 US disclosed
US-12318422-B2 Tannin-based antiproliferative pharmaceutical IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2025-06-03 US disclosed
US-12274730-B2 Flavonoid compositions and methods of use BERKLEY, LLC (US) 2025-04-15 US disclosed
EP-1546340-A4 FLAVANOID 3',5'HYDROXYLASE GENE SEQUENCES AND USES THEREFOR INTERNAT FLOWERS DEVELOPMENTS (AU) 2007-08-08 EP disclosed
US-20070150984-A1 Genetic sequences having methyltransferase activity and uses therefor INTERNATIONAL FLOWER DEVELOPMENTS PTY.LTD. OF COLLINGWOOD (AU) 2007-06-28 US disclosed
EP-1478753-A4 GENETIC SEQUENCES HAVING METHYLTRANSFERASE ACTIVITY AND USES THEREFOR INTERNAT FLOWERS DEVELOPMENTS (AU) 2007-03-28 EP disclosed
US-20070033674-A1 Flavanoid 3',5' hydroxylase gene sequences and uses therefor SUNTORY HOLDINGS LIMITED (JP) 2007-02-08 US disclosed
EP-1546340-A1 FLAVANOID 3',5'HYDROXYLASE GENE SEQUENCES AND USES THEREFOR INTERNATIONAL FLOWER DEVELOPMENTS Pty. Ltd. (AU) 2005-06-29 EP disclosed
EP-1478753-A1 GENETIC SEQUENCES HAVING METHYLTRANSFERASE ACTIVITY AND USES THEREFOR INTERNATIONAL FLOWER DEVELOPMENTS Pty. Ltd. (AU) 2004-11-24 EP disclosed
WO-2004020637-A1 FLAVONOID 3',5'HYDROXYLASE GENE SEQUENCES AND USES THEREFOR INTERNATIONAL FLOWER DEVELOPMENTS PTY. LTD. (AU) 2004-03-11 WO disclosed
WO-2003062428-A1 GENETIC SEQUENCES HAVING METHYLTRANSFERASE ACTIVITY AND USES THEREFOR INTERNATIONAL FLOWER DEVELOPMENTS PTY LTD (AU) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230355769-A1 COMPOSITIONS, CONTAINERS, AND METHODS RELATED TO FLAVYLIUM EXCIPIENTS CNR2, CNR1, UGT8 CD38 2308/4885DPP4 4789/4885MAOA 831/4885
US-20230338331-A1 COMPOSITIONS, CONTAINERS, AND METHODS RELATED TO FLAVYLIUM EXCIPIENTS CNR2, CNR1, UGT8 CD38 2308/4885DPP4 4789/4885MAOA 831/4885
US-20250249063-A1 METHOD FOR TREATING ORAL CANCER UGGT1, G6PD, UGT1A3 CD38 1656/4885DPP4 176/4885MAOA 3217/4885
US-12569530-B2 Tannin-based antiproliferative pharmaceutical SLC2A3, SLC2A1, SLC2A8 CD38 2712/4885DPP4 478/4885MAOA 3606/4885
US-12318422-B2 Tannin-based antiproliferative pharmaceutical UGGT1, G6PD, UGDH CD38 1949/4885DPP4 150/4885MAOA 3285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.